Hi OHM, could you please speak to the length of th

Quote:

---

Hi OHM, could you please speak to the length of the CRC trial ? It's not clear to me. Thank you.

"TAS-102 and bevacizumab will be administered for three of four weeks in a four-week cycle, and leronlimab (at doses of 350 mg or 700 mg) will be administered weekly. The study will include a safety lead-in treating five patients in the 350 mg leronlimab arm prior to beginning enrollment to the 700 mg leronlimab arm."

---

Cytodyn hasn't released the trial length but the dosing schedule from your post has nothing to do with trial length. Looking at a bunch of phase 2 CRC trials, primary trial length is generally a year with follow-up of up to two years. Trial results would be released after the primary trial is done.

I took a look at the results from the phase 3 TAS-102/bevacizumab trial for CRC. With an median overall survival (mOS) of 10.8 months and a median progression free survival (mPFS) of 5.6 months a one year leronlimab trial is long enough to prove superiority. 57% of patients dead at one year certainly needs to be improved upon.

Quote:

---

Patients treated with bevacizumab plus TAS-102 (n = 246) achieved a median OS of 10.8 months vs 7.5 months in patients treated with TAS-102 alone (HR, 0.61; 95% CI, 0.49-0.77; P < .001). The 6- and 12-month OS rates in the bevacizumab arm were 77% and 43%, respectively.

Additional data showed that patients in the bevacizumab arm experienced a median PFS of 5.6 months vs 2.4 months with TAS-102 alone (HR, 0.44; 95% CI, 0.36-0.54; P < .001). The 6- and 12- month PFS rates in the bevacizumab arm were 43% and 16%, respectively, compared with 16% and 1% in the control arm, respectively.
https://www.onclive.com/view/bevacizumab-plus...-line-mcrc

---